Clinical Trial:
Topical CBD for Rheumatoid Arthritis Relief

In partnership with Western Sydney University’s NICM Health Research Institute

We’re proud to support a world-first clinical trial investigating the effectiveness of our high-strength CBD salve in managing symptoms of rheumatoid arthritis – a debilitating autoimmune condition that affects 1 in 50 Australians.

Our first study is a preliminary 4-week, open label study targeting patients with poorly managed rheumatoid arthritis. If successful this will be followed by a randomised, placebo-controlled trial. This will be conducted by NICM Health Research Institute, Western Sydney University in collaboration with the Department of Rheumatology at Westmead Hospital.

NICM is Australia’s leading institute for integrative medicine research. Over the course of four weeks, participants apply a topical cannabidiol (CBD) salve directly to painful joints. Researchers are assessing changes in pain, inflammation, joint function, and overall quality of life.

Cost of inaction is rising Arthritis-related healthcare costs are projected to exceed $11.92 billion by 2040 in Australia alone.

For further details on the study please visit this page.

Stay Updated

As the trial progresses, we’ll be sharing updates, expert insights, and participant experiences right here.

Sign up to our newsletter to receive the latest findings and announcements straight to your inbox.

Together, we’re building the evidence base for a future where natural therapies play a powerful role in pain management.

Clinical Trial Newsletter Updates

* indicates required
OMG Pharma
60 Martin Place,
Sydney NSW 2000 
omgpharma.com.au